1Spacing (bp) between mutations 1 and 2, followed by the spacing between mutations 2 and 3, etc. 2Drug Response: PR-partial response; SD-stable disease; PD-progressive disease. 3The deletion is presum
Background: We have reported that BRAF V600E mutations and microsatellite instability-high (MSI-H) are more prevalent in a population-based cohort of metastatic colorectal cancer (mCRC)
